Expression of mesothelin in thymic carcinoma and its potential therapeutic significance
- 1 November 2016
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 101, 104-110
Abstract
No abstract availableKeywords
Funding Information
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
This publication has 29 references indexed in Scilit:
- A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational StudyClinical Cancer Research, 2014
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical DevelopmentMolecular Cancer Therapeutics, 2012
- Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancersClinical Chemistry and Laboratory Medicine (CCLM), 2011
- Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing CancersClinical Cancer Research, 2010
- High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBritish Journal of Cancer, 2009
- Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic MarkerCancer Epidemiology, Biomarkers & Prevention, 2006
- Application of Mesothelin Immunostaining in Tumor DiagnosisAmerican Journal of Surgical Pathology, 2003
- Value of Mesothelin Immunostaining in the Diagnosis of MesotheliomaLaboratory Investigation, 2003
- Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)2001
- Thymoma: Histologic subclassification is an independent prognostic factorCancer, 1994